STAGE III BLADDER CANCER AJCC V8

This early-phase study tests two or three drugs together (cabozantinib, nivolumab, and sometimes ipilimumab) in people with advanced cancers of the urinary and genital systems that have spread. The main goals are to find the safest dose and understand side effects. About 152 adul…

This study tests whether adding the chemotherapy drug eribulin to the immunotherapy atezolizumab works better than atezolizumab alone for people with advanced bladder cancer that has spread. The trial includes 72 adults whose cancer cannot be treated with the standard cisplatin c…

This study tests a drug called olaparib in people with advanced bladder or related cancers that have certain DNA repair problems. The drug works by blocking a protein that helps cancer cells fix themselves, which may stop tumor growth. About 60 adults with these specific gene cha…

This study was designed for people with muscle-invasive bladder cancer who cannot receive the standard chemotherapy drug cisplatin. It aimed to test whether the targeted therapy erdafitinib, alone or combined with the immunotherapy atezolizumab, could shrink tumors before surgery…

This study tests whether adding tocilizumab to standard immunotherapy (ipilimumab and nivolumab) can reduce severe side effects in people with advanced melanoma, lung cancer, or bladder cancer. About 35 participants will receive the combination to see if it is safer and still eff…

This early-phase study tests a combination of two drugs—tazemetostat and pembrolizumab—in people with advanced bladder cancer that has spread. Tazemetostat blocks certain enzymes that help cancer grow, while pembrolizumab helps the immune system fight the cancer. The goal is to f…

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy and radiation can improve outcomes for people with stage III bladder cancer that has spread to nearby lymph nodes. About 95 adults will receive either chemoradiation alone or chemoradiation…

This study tests whether adding cabozantinib to avelumab (an immunotherapy) helps keep metastatic urothelial cancer from progressing after initial chemotherapy. About 654 adults with advanced bladder, kidney, or ureter cancer that has spread will receive either the combo or avelu…

This study looks at whether specific gene mutations (ARID1A and KDM6A) and a protein called CXCL13 can predict how well the immunotherapy drug nivolumab works in people with advanced bladder cancer that has spread. About 6 participants with these gene changes will receive nivolum…